Incyte Corporation (INCY)
Red blood cells carry oxygen to all parts of your body. They also remove carbon dioxide (a waste product) from your body’s cells and carry it to the lungs to be exhaled.
Red blood cells are made in your bone marrow—a sponge-like tissue inside the bones. White blood cells and platelets also are made in your bone marrow. White blood cells help fight infection. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding.
Polycythemia vera is a chronic, incurable blood cancer associated with an overproduction of blood cells. This leads to a thickening of the blood and increased risk of blood clots. These clots can cause serious cardiovascular complications, such as stroke and heart attack, resulting in increased morbidity and mortality.
A mutation, or change, in the body’s JAK2 gene is the major cause of polycythemia vera. This gene makes a protein that helps the body produce blood cells.
Patients with polycythemia vera often have enlarged spleen and additional debilitating symptoms. Many patients treated with commonly available therapies become intolerant or resistant, which is associated with an increased of risk of progression
It may occur at any age but often presents later in life, with a median age at diagnosis of 60 years. Approximately 100,000 patients in the United States are living with polycythemia vera and approximately 25 percent of patients with it develop resistance to or intolerance of hydroxyurea
INCY reported that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of maintaining hematocrit control (red blood cell volume) without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reducing spleen size by 35 percent or more.
The safety profile of ruxolitinib was generally consistent with previous studies based on initial review of the data.
Ruxolitinib, an oral inhibitor of the JAK1 and JAK2 tyrosine kinases, is marketed by INCY as Jakafi(R) in the U.S., and by Novartis as Jakavi(R) outside the U.S.
Data from Phase III trial are expected to be presented at an upcoming scientific meeting and a supplemental new drug application is planned for submission to U.S. FDA this year
INCY‘s Jakafi(R) (ruxolitinib) is a prescription medicine approved by the U.S. FDA to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
INCY is focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation.
More about Incyte Corporation (INCY) at www.incyte.com
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada, which business model is based on selling advertising to local businesses.
CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.
CRWE presently has more than 80 U.S. cities, 9 cities from Canada and is currently adding 100 new sites throughout California.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Information Services Group, Inc. (III)
Keep a close eye on III. The company finished a record year with a strong fourth-quarter performance on its unaudited financial results.
For the fourth quarter 2013, III posted record fourth-quarter revenues of $53.4 million, an 8% increase year over year, operating income of $3.0 million, versus $1.7 million in the same period the prior year, and net income of $957,000, compared to $149,000 in the fourth quarter 2012.
For full year 2014, III is targeting revenues between $215-$225 million and adjusted EBITDA between $23-$26 million.
III is a leading technology insights, market intelligence and advisory services company. It supports private and public sector organizations to transform and optimize their operational environments through research, benchmarking, consulting and managed services, with a focus on information technology, business process transformation, program management services and enterprise resource planning
More about Information Services Group, Inc. (III) at www.isg-one.com.
Read Full Disclaimer at www.pennyomega.com/disclaimer